Home / Companies / Protalix BioTherapeutics, Inc. / 13 Jul 2023
Protalix BioTherapeutics, Inc.: meeting of 13 Jul 2023
Votes reported on Form N-PX, item by item
41 Form N-PX filers reported votes at the Protalix BioTherapeutics, Inc. meeting of 13 Jul 2023. Their records fall into 6 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
7 nominees; 74.3% of reported votes for; 5 filers withheld from or voted against at least one nominee.
42 vote records from 6 filers. 0 of the 5 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
41 vote records from 39 filers. 2 of the 33 filers that marked the item either way voted against management. 6 filers reported this item without a management mark.
SECTION 14A SAY-ON-PAY VOTESIssuer
Frequency of the say-on-pay vote
one year: 31 filers; not applicable: 2 filers; against: 1 filer; : 1 filer.
40 vote records from 38 filers. 0 of the 32 filers that marked the item either way voted against management. 6 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
6 vote records from 6 filers. 0 of the 5 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
CAPITAL STRUCTUREIssuer
CAPITAL STRUCTURE: management items
Management items in this category are shown together; filers word and number them differently.
6 vote records from 6 filers. 0 of the 5 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
COMPENSATIONIssuer
COMPENSATION: management items
Management items in this category are shown together; filers word and number them differently.
11 vote records from 8 filers. 0 of the 7 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Pay-vote frequency | 4. Auditor |
|---|---|---|---|---|
| BlackRock and iShares | For | For | Split or no vote | For |
| Equitable | For | For | Split or no vote | For |
| John Hancock and Manulife | For | For | Split or no vote | For |
| Goldman Sachs | No report | Split or no vote | Split or no vote | No report |
| Northern Trust and FlexShares | For | For | Split or no vote | For |
| Victory Capital | For | For | Split or no vote | For |
| Columbia Threadneedle | No report | Against * | Split or no vote | No report |
| Federated Hermes | No report | For | Split or no vote | No report |
| Neuberger Berman | No report | For | Split or no vote | No report |
| Baird | No report | For | Split or no vote | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Protalix BioTherapeutics, Inc. meeting?
41 Form N-PX filers reported votes at the meeting of 13 Jul 2023. On say-on-pay, 2 of 33 voted against management (6.1%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Protalix BioTherapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Protalix BioTherapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Protalix BioTherapeutics, Inc. with a meeting date within three days of 13 Jul 2023. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.